161 related articles for article (PubMed ID: 26536195)
21. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
[TBL] [Abstract][Full Text] [Related]
22. MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.
Flacco A; Ludovini V; Bianconi F; Ragusa M; Bellezza G; Tofanetti FR; Pistola L; Siggillino A; Vannucci J; Cagini L; Sidoni A; Puma F; Varella-Garcia M; Crinò L
Am J Clin Oncol; 2015 Apr; 38(2):152-8. PubMed ID: 25806711
[TBL] [Abstract][Full Text] [Related]
23. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.
Perner S; Wagner PL; Soltermann A; LaFargue C; Tischler V; Weir BA; Weder W; Meyerson M; Giordano TJ; Moch H; Rubin MA
J Pathol; 2009 Jan; 217(1):65-72. PubMed ID: 18932182
[TBL] [Abstract][Full Text] [Related]
24. FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.
Flockerzi FA; Roggia C; Langer F; Holleczek B; Bohle RM
Virchows Arch; 2018 May; 472(5):759-769. PubMed ID: 29270870
[TBL] [Abstract][Full Text] [Related]
25. Investigation of HER2 overexpression in non-small cell lung cancer.
Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
[TBL] [Abstract][Full Text] [Related]
26. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
Kubokura H; Tenjin T; Akiyama H; Koizumi K; Nishimura H; Yamamoto M; Tanaka S
Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):197-203. PubMed ID: 11578259
[TBL] [Abstract][Full Text] [Related]
27. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.
Preusser M; Berghoff AS; Ilhan-Mutlu A; Magerle M; Dinhof C; Widhalm G; Dieckmann K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; von Deimling A; Schoppmann SF; Zielinski CC; Streubel B; Birner P
Lung Cancer; 2013 Jun; 80(3):278-83. PubMed ID: 23453647
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer.
Miao JL; Liu RJ; Zhou JH; Meng SH
Chin Med J (Engl); 2016 Dec; 129(23):2868-2872. PubMed ID: 27901003
[TBL] [Abstract][Full Text] [Related]
30. The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data.
Wang Y; Gao W; Xu J; Chen X; Yang Y; Zhu Y; Yin Y; Guo R; Liu P; Shu Y; Liu L
Biomed Res Int; 2015; 2015():763080. PubMed ID: 26788508
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
[TBL] [Abstract][Full Text] [Related]
33. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.
Preusser M; Berghoff AS; Berger W; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; von Deimling A; Streubel B; Birner P
Lung Cancer; 2014 Jan; 83(1):83-9. PubMed ID: 24183471
[TBL] [Abstract][Full Text] [Related]
34. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.
Baty F; Facompré M; Kaiser S; Schumacher M; Pless M; Bubendorf L; Savic S; Marrer E; Budach W; Buess M; Kehren J; Tamm M; Brutsche MH
Am J Respir Crit Care Med; 2010 Jan; 181(2):181-8. PubMed ID: 19833826
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
[TBL] [Abstract][Full Text] [Related]
36. BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification.
Jiang BY; Zhang XC; Su J; Meng W; Yang XN; Yang JJ; Zhou Q; Chen ZY; Chen ZH; Xie Z; Chen SL; Wu YL
Mol Cancer; 2013 Jun; 12():61. PubMed ID: 23758992
[TBL] [Abstract][Full Text] [Related]
37. Expression of Cystatin SN significantly correlates with recurrence, metastasis, and survival duration in surgically resected non-small cell lung cancer patients.
Cao X; Li Y; Luo RZ; Zhang L; Zhang SL; Zeng J; Han YJ; Wen ZS
Sci Rep; 2015 Feb; 5():8230. PubMed ID: 25648368
[TBL] [Abstract][Full Text] [Related]
38. Correlation of EGFR gene amplification with invasion and metastasis of non-small cell lung cancer.
Jia XF; Li J; Zhao HB; Liu J; Liu JJ
Genet Mol Res; 2015 Sep; 14(3):11006-12. PubMed ID: 26400330
[TBL] [Abstract][Full Text] [Related]
39. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer.
Vincenten J; Smit EF; Vos W; Grünberg K; Postmus PE; Heideman DA; Snijders PJ; Meijer G; Kuik J; Witte BI; Thunnissen E
J Thorac Oncol; 2012 Oct; 7(10):1522-7. PubMed ID: 22982653
[TBL] [Abstract][Full Text] [Related]
40. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
Göke F; Franzen A; Menon R; Goltz D; Kirsten R; Boehm D; Vogel W; Göke A; Scheble V; Ellinger J; Gerigk U; Fend F; Wagner P; Schroeck A; Perner S
Chest; 2012 Oct; 142(4):1020-1026. PubMed ID: 22499828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
